Respiratory syncytial virus vaccine

Patent metadata

Field	Value
Publication number	US-9409973-B2
Application number	US-201113885388-A
Country	US
Kind code	B2
Filing date	Nov 15, 2011
Priority date	Nov 15, 2010
Publication date	Aug 9, 2016
Grant date	Aug 9, 2016

Abstract

Described is a vaccine against Respiratory Syncytial Virus (RSV). More specifically, described is a recombinant subunit vaccine comprising the ectodomain of the RSV-encoded Small Hydrophobic (SH) protein. The ectodomain of SH is referred to as SHe. The ectodomain is typically presented as an oligomer, or a pentamer. Further described are antibodies, raised against the ectodomain or specific for the ectodomain, and their use for protecting a subject against RSV infection and/or for treatment of an infected subject.

First claim

The invention claimed is:

1. A method of evoking protective immunity in a subject against Respiratory Syncytial Virus infection, the method comprising:
administering to a subject in need thereof an immunogenic composition comprising the ectodomain of the small hydrophobic protein of a Respiratory Syncytial Virus, wherein the ectodomain comprises SEQ ID NO: 1, wherein the composition comprises a carrier heterologous to the ectodomain, and wherein the cysteine residue at position 4 is optionally replaced with a serine residue.

2. The method of claim 1 , wherein said ectodomain is presented as an oligomer.

3. The method of claim 1 , wherein the ectodomain is genetically linked to the carrier.

4. The method of claim 1 , wherein the ectodomain is chemically linked to the carrier.

5. The method of claim 1 , wherein the carrier is an oligomer.

6. The method of claim 5 , wherein said oligomer is a pentamer.

7. The method of claim 1 , wherein the carrier is selected from the group consisting of Cartilage Oligomeric Matrix Protein (comp), Lpp-56, and a virus-like particle.

8. The method of claim 1 , wherein the ectodomain comprises SEQ ID NO: 1.

9. The method of claim 1 , wherein the ectodomain comprises SEQ ID NO: 1 with the cysteine residue at position 4 replaced with a serine residue.

10. The method of claim 1 , comprising administering the immunogenic composition to the subject prior to exposure of the subject to Respiratory Syncytial Virus.

11. The method of claim 1 , wherein the carrier is a non-proteinaceous carrier.

12. The method of claim 11 , wherein the non-proteinaceous carrier is a liposome.

Assignees

• Saelens Xavier
• Schepens Bert
• Fiers Walter
• Vib Vzw
• Univ Gent

Inventors

• Saelens Xavier
• Schepens Bert
• Fiers Walter

Classifications

• A61K2039/55566

  Emulsions, e.g. Freund's adjuvant, MF59 · CPC title

• C12N2760/18534

  Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein · CPC title

• C07K14/78

  Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG] · CPC title

• A61K2039/575

  humoral response · CPC title

• A61K2039/55505

  Inorganic adjuvants · CPC title